Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · Real-Time Price · USD
1.750
+0.020 (1.14%)
At close: Apr 1, 2025, 4:00 PM
1.744
-0.006 (-0.34%)
After-hours: Apr 1, 2025, 4:42 PM EDT
Regulus Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Regulus Therapeutics stock have an average target of 11.8, with a low estimate of 6.00 and a high estimate of 28. The average target predicts an increase of 574.29% from the current stock price of 1.75.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Regulus Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $3 → $6 | Hold → Buy | Upgrades | $3 → $6 | +242.86% | Mar 27, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $28 | Strong Buy | Maintains | $28 | +1,500.00% | Mar 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +471.43% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +471.43% | Feb 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +471.43% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.04
from -0.82
EPS Next Year
-1.16
from -1.04
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 185.6M | ||
| Avg | n/a | n/a | 90.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.99 | -1.09 | 0.60 | ||
| Avg | -1.04 | -1.16 | 0.58 | ||
| Low | -1.12 | -1.19 | 0.56 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.